In a study appearing in Nature, researchers from China, France, and the UK described a gut microbiome signature for identifying individuals with liver cirrhosis. After tossing out gut microbial community members that seemed to be shared between individuals with liver cirrhosis and other conditions such as type 2 diabetes and inflammatory bowel disease, the investigators were left with 15 bacterial species suspected of being specific to liver cirrhosis. They noted that the overall diversity and gene richness was higher in the gut microbial communities from healthy individuals studied.
Saying that it does not believe its Chemical and Applied Markets division can achieve "acceptable financial performance" in the next two years, Bruker said that it plans to sell and/or restructure certain parts of the CAM business, resulting in an expected 200 to 250 layoffs. Bruker said the planned actions would result in a reduction in annual run-rate revenues of between $50 million and $70 million, while profits are estimated to improve by $15 million to $20 million per year upon the completion of the reorganization. CAM was formed in 2010 following Bruker's purchase of certain Varian businesses.
US Senator Tom Harkin (D – Iowa) plans to introduce the Accelerating Biomedical Research Act sometime later this month in an effort to let NIH restore some of the funding it has lost in recent years due to flat budgets and sequestration. The legislation would free up appropriators in the Senate and House of Representatives and target NIH for funding boosts while other agencies would remain stuck under hard spending caps imposed last year. If the legislation, currently still in draft form, passes, NIH could see an increase of nearly $3 billion next year. By 2021, NIH would receive as much as $46.2 billion.
This online seminar will discuss the discovery and evaluation of gene expression signatures associated with cancer treatment outcomes. These presentations will provide an overview of the promise of tumor microenvironment profiling in the radiation oncology setting, as well as the challenges in applying genomic methods to biomarker discovery.